{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:31:52Z","timestamp":1794493912004,"version":"4.9.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["BT\/PR34488\/MED\/15\/221\/2022(SP094)"],"award-info":[{"award-number":["BT\/PR34488\/MED\/15\/221\/2022(SP094)"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-08582-y","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:43:53Z","timestamp":1759171433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adjuvant activity of a small molecule TLR4 agonist discovered via structure-based virtual screening"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3565-1543","authenticated-orcid":false,"given":"Mohammad","family":"Kadivella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4587-5719","authenticated-orcid":false,"given":"Vivek P.","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6666-4887","authenticated-orcid":false,"given":"Jusail","family":"CP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3676-4822","authenticated-orcid":false,"given":"Sridhar","family":"Kavela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-483X","authenticated-orcid":false,"given":"Sarwar","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8736-5170","authenticated-orcid":false,"given":"Syed M.","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"8582_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal. Transduct. Target. Ther. 8, 283 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"8582_CR2","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597\u20131608 (2013).","journal-title":"Nat. Med."},{"key":"8582_CR3","doi-asserted-by":"publisher","unstructured":"Facciola, A., Visalli, G., Lagana, A. & Di Pietro, A. An overview of vaccine adjuvants: current evidence and future perspectives. Vaccines 10, https:\/\/doi.org\/10.3390\/vaccines10050819 (2022).","DOI":"10.3390\/vaccines10050819"},{"key":"8582_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1128\/CMR.00046-08","volume":"22","author":"TH Mogensen","year":"2009","unstructured":"Mogensen, T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240\u2013273 (2009). Table of Contents.","journal-title":"Clin. Microbiol. Rev."},{"key":"8582_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783\u2013801 (2006).","journal-title":"Cell"},{"key":"8582_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373\u2013384 (2010).","journal-title":"Nat. Immunol."},{"key":"8582_CR7","doi-asserted-by":"publisher","first-page":"812774","DOI":"10.3389\/fimmu.2022.812774","volume":"13","author":"T Duan","year":"2022","unstructured":"Duan, T., Du, Y., Xing, C., Wang, H. Y. & Wang, R. F. Toll-like receptor signaling and its role in cell-mediated immunity. Front. Immunol. 13, 812774 (2022).","journal-title":"Front. Immunol."},{"key":"8582_CR8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00018-020-03656-y","volume":"78","author":"A Ciesielska","year":"2021","unstructured":"Ciesielska, A., Matyjek, M. & Kwiatkowska, K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell. Mol. Life Sci. 78, 1233\u20131261 (2021).","journal-title":"Cell. Mol. Life Sci."},{"key":"8582_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/ni1569","volume":"9","author":"JC Kagan","year":"2008","unstructured":"Kagan, J. C. et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 9, 361\u2013368 (2008).","journal-title":"Nat. Immunol."},{"key":"8582_CR10","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1126\/science.1138963","volume":"316","author":"V Mata-Haro","year":"2007","unstructured":"Mata-Haro, V. et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628\u20131632 (2007).","journal-title":"Science"},{"key":"8582_CR11","doi-asserted-by":"publisher","first-page":"e41144","DOI":"10.1371\/journal.pone.0041144","volume":"7","author":"MA Arias","year":"2012","unstructured":"Arias, M. A. et al. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One 7, e41144 (2012).","journal-title":"PLoS One"},{"key":"8582_CR12","doi-asserted-by":"publisher","first-page":"1043109","DOI":"10.3389\/fimmu.2023.1043109","volume":"14","author":"SK Verma","year":"2023","unstructured":"Verma, S. K. et al. New-age vaccine adjuvants, their development, and future perspective. Front. Immunol. 14, 1043109 (2023).","journal-title":"Front. Immunol."},{"key":"8582_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","volume":"26","author":"P Vandepapeliere","year":"2008","unstructured":"Vandepapeliere, P. et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26, 1375\u20131386 (2008).","journal-title":"Vaccine"},{"key":"8582_CR14","doi-asserted-by":"publisher","first-page":"577823","DOI":"10.3389\/fimmu.2020.577823","volume":"11","author":"YQ Wang","year":"2020","unstructured":"Wang, Y. Q., Bazin-Lee, H., Evans, J. T., Casella, C. R. & Mitchell, T. C. MPL adjuvant contains competitive antagonists of human TLR4. Front. Immunol. 11, 577823 (2020).","journal-title":"Front. Immunol."},{"key":"8582_CR15","doi-asserted-by":"publisher","unstructured":"Yang, J. X. et al. Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases. Pharmaceutics 14, https:\/\/doi.org\/10.3390\/pharmaceutics14020423 (2022).","DOI":"10.3390\/pharmaceutics14020423"},{"key":"8582_CR16","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1021\/acs.jmedchem.2c01998","volume":"66","author":"A Romerio","year":"2023","unstructured":"Romerio, A. et al. New Glucosamine-based TLR4 agonists: design, synthesis, mechanism of action, and in vivo activity as vaccine adjuvants. J. Med. Chem. 66, 3010\u20133029 (2023).","journal-title":"J. Med. Chem."},{"key":"8582_CR17","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1021\/acsmedchemlett.8b00566","volume":"9","author":"NM Shukla","year":"2018","unstructured":"Shukla, N. M., Chan, M., Hayashi, T., Carson, D. A. & Cottam, H. B. Recent advances and perspectives in small-molecule TLR ligands and their modulators. ACS Med. Chem. Lett. 9, 1156\u20131159 (2018).","journal-title":"ACS Med. Chem. Lett."},{"key":"8582_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ejmech.2013.10.019","volume":"70","author":"U Svajger","year":"2013","unstructured":"Svajger, U. et al. Novel toll-like receptor 4 (TLR4) antagonists identified by structure- and ligand-based virtual screening. Eur. J. Med. Chem. 70, 393\u2013399 (2013).","journal-title":"Eur. J. Med. Chem."},{"key":"8582_CR19","doi-asserted-by":"publisher","unstructured":"Perez-Regidor, L., Zarioh, M., Ortega, L. & Martin-Santamaria, S. Virtual screening approaches towards the discovery of toll-like receptor modulators. Int. J. Mol. Sci. 17, https:\/\/doi.org\/10.3390\/ijms17091508 (2016).","DOI":"10.3390\/ijms17091508"},{"key":"8582_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s42514-021-00086-5","volume":"4","author":"B Zhang","year":"2022","unstructured":"Zhang, B., Li, H., Yu, K. & Jin, Z. Molecular docking-based computational platform for high-throughput virtual screening. CCF Trans. high. Perform. Comput. 4, 63\u201374 (2022).","journal-title":"CCF Trans. high. Perform. Comput."},{"key":"8582_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejmech.2017.12.074","volume":"146","author":"J Honegr","year":"2018","unstructured":"Honegr, J. et al. Rational design of novel TLR4 ligands by in silico screening and their functional and structural characterization in vitro. Eur. J. Med. Chem. 146, 38\u201346 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"8582_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., P, S. A. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug. Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"8582_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1084\/jem.20051720","volume":"203","author":"T Querec","year":"2006","unstructured":"Querec, T. et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.  J. Exp. Med. 203, 413\u2013424 (2006).","journal-title":"J. Exp. Med."},{"key":"8582_CR24","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.4049\/jimmunol.179.7.4711","volume":"179","author":"S Koyama","year":"2007","unstructured":"Koyama, S. et al. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J. Immunol. 179, 4711\u20134720 (2007).","journal-title":"J. Immunol."},{"key":"8582_CR25","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/bloodadvances.2017011411","volume":"1","author":"JR Francica","year":"2017","unstructured":"Francica, J. R. et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv. 1, 2329\u20132342 (2017).","journal-title":"Blood Adv."},{"key":"8582_CR26","doi-asserted-by":"publisher","unstructured":"Petitdemange, C. et al. Vaccine induction of antibodies and tissue-resident CD8\u2009+\u2009T cells enhances protection against mucosal SHIV-infection in young macaques. JCI insight 4, https:\/\/doi.org\/10.1172\/jci.insight.126047 (2019).","DOI":"10.1172\/jci.insight.126047"},{"key":"8582_CR27","doi-asserted-by":"publisher","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","volume":"183","author":"AM Didierlaurent","year":"2009","unstructured":"Didierlaurent, A. M. et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183, 6186\u20136197 (2009).","journal-title":"J. Immunol."},{"key":"8582_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","volume":"16","author":"AM Didierlaurent","year":"2017","unstructured":"Didierlaurent, A. M. et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev. Vaccines 16, 55\u201363 (2017).","journal-title":"Expert Rev. Vaccines"},{"key":"8582_CR29","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1007\/s00018-008-8228-6","volume":"65","author":"CR Casella","year":"2008","unstructured":"Casella, C. R. & Mitchell, T. C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 65, 3231\u20133240 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"8582_CR30","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1039\/b809090d","volume":"6","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y., Gaekwad, J., Wolfert, M. A. & Boons, G. J. Synthetic tetra-acylated derivatives of lipid A from Porphyromonas gingivalis are antagonists of human TLR4. Org. Biomol. Chem. 6, 3371\u20133381 (2008).","journal-title":"Org. Biomol. Chem."},{"key":"8582_CR31","doi-asserted-by":"publisher","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","volume":"6","author":"RN Coler","year":"2011","unstructured":"Coler, R. N. et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PloS one 6, e16333 (2011).","journal-title":"PloS one"},{"key":"8582_CR32","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1128\/CVI.00153-07","volume":"14","author":"GL Morefield","year":"2007","unstructured":"Morefield, G. L., Hawkins, L. D., Ishizaka, S. T., Kissner, T. L. & Ulrich, R. G. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Clin. Vaccine Immunol. 14, 1499\u20131504 (2007).","journal-title":"Clin. Vaccine Immunol."},{"key":"8582_CR33","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/nature07830","volume":"458","author":"BS Park","year":"2009","unstructured":"Park, B. S. et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458, 1191\u20131195 (2009).","journal-title":"Nature"},{"key":"8582_CR34","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1586\/14760584.6.5.773","volume":"6","author":"ST Ishizaka","year":"2007","unstructured":"Ishizaka, S. T. & Hawkins, L. D. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev. Vaccines 6, 773\u2013784 (2007).","journal-title":"Expert Rev. Vaccines"},{"key":"8582_CR35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jconrel.2013.07.030","volume":"172","author":"MT Orr","year":"2013","unstructured":"Orr, M. T. et al. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J. Control. Rel. 172, 190\u2013200 (2013).","journal-title":"J. Control. Rel."},{"key":"8582_CR36","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1021\/acs.jmedchem.2c01642","volume":"66","author":"D Ding","year":"2023","unstructured":"Ding, D. et al. Self-adjuvanting protein vaccine conjugated with a novel synthetic TLR4 agonist on virus-like liposome induces potent immunity against SARS-CoV-2. J. Medicinal Chem. 66, 1467\u20131483 (2023).","journal-title":"J. Medicinal Chem."},{"key":"8582_CR37","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.1021\/acs.jmedchem.3c02385","volume":"67","author":"R Rohokale","year":"2024","unstructured":"Rohokale, R., Guo, J. & Guo, Z. Monophosphoryl Lipid A-Rhamnose Conjugates as a New Class of Vaccine Adjuvants. J. Med. Chem. 67, 7458\u20137469 (2024).","journal-title":"J. Med. Chem."},{"key":"8582_CR38","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.1039\/c3cs60039d","volume":"42","author":"X Wang","year":"2013","unstructured":"Wang, X., Smith, C. & Yin, H. Targeting Toll-like receptors with small molecule agents. Chem. Soc. Rev. 42, 4859\u20134866 (2013).","journal-title":"Chem. Soc. Rev."},{"key":"8582_CR39","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.1021\/jm400620g","volume":"56","author":"DB Salunke","year":"2013","unstructured":"Salunke, D. B. et al. Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants. J. Med. Chem. 56, 5885\u20135900 (2013).","journal-title":"J. Med. Chem."},{"key":"8582_CR40","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1021\/jm301694x","volume":"56","author":"M Chan","year":"2013","unstructured":"Chan, M. et al. Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands. J. Med. Chem. 56, 4206\u20134223 (2013).","journal-title":"J. Med. Chem."},{"key":"8582_CR41","first-page":"E884","volume":"113","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. TLR4\/MD-2 activation by a synthetic agonist with no similarity to LPS. Proc. Natl. Acad. Sci. USA 113, E884\u2013E893 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8582_CR42","doi-asserted-by":"publisher","first-page":"8082","DOI":"10.1021\/acs.jmedchem.6b00872","volume":"59","author":"M Beesu","year":"2016","unstructured":"Beesu, M., Salyer, A. C., Trautman, K. L., Hill, J. K. & David, S. A. Human Toll-like Receptor (TLR) 8-specific agonistic activity in substituted Pyrimidine-2,4-diamines. J. Med. Chem. 59, 8082\u20138093 (2016).","journal-title":"J. Med. Chem."},{"key":"8582_CR43","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1016\/j.bmcl.2011.04.050","volume":"21","author":"NM Shukla","year":"2011","unstructured":"Shukla, N. M. et al. Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines. Bioorg. Med. Chem. Lett. 21, 3232\u20133236 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"8582_CR44","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1039\/c2ob26705e","volume":"11","author":"HP Kokatla","year":"2013","unstructured":"Kokatla, H. P. et al. Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines. Org. Biomol. Chem. 11, 1179\u20131198 (2013).","journal-title":"Org. Biomol. Chem."},{"key":"8582_CR45","doi-asserted-by":"publisher","first-page":"15665","DOI":"10.1021\/acsomega.9b02138","volume":"4","author":"JT Evans","year":"2019","unstructured":"Evans, J. T. et al. Synthetic Toll-like Receptors 7 and 8 agonists: structure-activity relationship in the Oxoadenine series. ACS Omega 4, 15665\u201315677 (2019).","journal-title":"ACS Omega"},{"key":"8582_CR46","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1021\/jm100070n","volume":"53","author":"A Kurimoto","year":"2010","unstructured":"Kurimoto, A. et al. Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept. J. Med. Chem. 53, 2964\u20132972 (2010).","journal-title":"J. Med. Chem."},{"key":"8582_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","volume":"2","author":"DJ Dowling","year":"2018","unstructured":"Dowling, D. J. Recent advances in the discovery and delivery of TLR7\/8 agonists as vaccine adjuvants. ImmunoHorizons 2, 185\u2013197 (2018).","journal-title":"ImmunoHorizons"},{"key":"8582_CR48","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/cbic.201600639","volume":"18","author":"V Fagan","year":"2017","unstructured":"Fagan, V. et al. Synthesis, characterization and immunological evaluation of self-adjuvanting group a streptococcal vaccine candidates bearing various lipidic adjuvanting Moieties. Chembiochem: Eur. J. Chem. Biol. 18, 545\u2013553 (2017).","journal-title":"Chembiochem: Eur. J. Chem. Biol."},{"key":"8582_CR49","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1345\/aph.1L504","volume":"43","author":"AL Chan","year":"2009","unstructured":"Chan, A. L., Leung, H. W., Lu, C. L. & Lin, S. J. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.  Ann. Pharmacother. 43, 296\u2013303 (2009).","journal-title":"Ann. Pharmacother."},{"key":"8582_CR50","doi-asserted-by":"publisher","unstructured":"Perez-Regidor, L. et al. Small molecules as toll-like Receptor 4 modulators drug and in-house computational repurposing. Biomedicines 10, https:\/\/doi.org\/10.3390\/biomedicines10092326 (2022).","DOI":"10.3390\/biomedicines10092326"},{"key":"8582_CR51","doi-asserted-by":"publisher","first-page":"e813s","DOI":"10.6061\/clinics\/2018\/e813s","volume":"73","author":"CRK Paier","year":"2018","unstructured":"Paier, C. R. K. et al. Natural products as new antimitotic compounds for anticancer drug development. Clinics 73, e813s (2018).","journal-title":"Clinics"},{"key":"8582_CR52","doi-asserted-by":"publisher","first-page":"e0164632","DOI":"10.1371\/journal.pone.0164632","volume":"11","author":"JD Marshall","year":"2016","unstructured":"Marshall, J. D. et al. A Novel class of small molecule agonists with preference for human over mouse TLR4 activation. PlLoS One 11, e0164632 (2016).","journal-title":"PlLoS One"},{"key":"8582_CR53","doi-asserted-by":"publisher","first-page":"7114","DOI":"10.1080\/07391102.2021.1894987","volume":"40","author":"Z Fakhar","year":"2022","unstructured":"Fakhar, Z., Hejazi, L., Tabatabai, S. A. & Munro, O. Q. Discovery of novel heterocyclic amide-based inhibitors: an integrative in-silico approach to targeting soluble epoxide hydrolase. J. Biomol. Struct. Dyn. 40, 7114\u20137128 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"8582_CR54","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.drudis.2019.03.015","volume":"24","author":"LLG Ferreira","year":"2019","unstructured":"Ferreira, L. L. G. & Andricopulo, A. D. ADMET modeling approaches in drug discovery. Drug. Discov. Today 24, 1157\u20131165 (2019).","journal-title":"Drug. Discov. Today"},{"key":"8582_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jmgm.2014.11.010","volume":"56","author":"R Dolezal","year":"2015","unstructured":"Dolezal, R. et al. Ligand-based 3D QSAR analysis of reactivation potency of mono- and bis-pyridinium aldoximes toward VX-inhibited rat acetylcholinesterase. J. Mol. Graph. Model. 56, 113\u2013129 (2015).","journal-title":"J. Mol. Graph. Model."},{"key":"8582_CR56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ecoenv.2012.11.020","volume":"89","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Docking and CoMSIA studies on steroids and non-steroidal chemicals as androgen receptor ligands. Ecotoxicol. Environ. Saf. 89, 143\u2013149 (2013).","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"8582_CR57","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fimmu.2014.00316","volume":"5","author":"C Vaure","year":"2014","unstructured":"Vaure, C. & Liu, Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front. Immunol. 5, 316 (2014).","journal-title":"Front. Immunol."},{"key":"8582_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00514-9","volume":"7","author":"S Xu","year":"2022","unstructured":"Xu, S. et al. Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans. NPJ Vaccines 7, 90 (2022).","journal-title":"NPJ Vaccines"},{"key":"8582_CR59","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1016\/j.bbagen.2017.07.011","volume":"1861","author":"MS Murgueitio","year":"2017","unstructured":"Murgueitio, M. S. et al. Enhanced immunostimulatory activity of in silico discovered agonists of Toll-like receptor 2 (TLR2). Biochim. Biophys. acta. Gen. Subj. 1861, 2680\u20132689 (2017).","journal-title":"Biochim. Biophys. acta. Gen. Subj."},{"key":"8582_CR60","first-page":"5","volume":"11","author":"M Triantafilou","year":"2005","unstructured":"Triantafilou, M. & Triantafilou, K. The dynamics of LPS recognition: complex orchestration of multiple receptors. J. Endotoxin Res. 11, 5\u201311 (2005).","journal-title":"J. Endotoxin Res."},{"key":"8582_CR61","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1111\/bph.13221","volume":"172","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis. Br. J. Pharmacol. 172, 4391\u20134405 (2015).","journal-title":"Br. J. Pharmacol."},{"key":"8582_CR62","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4049\/jimmunol.170.1.413","volume":"170","author":"K Kawasaki","year":"2003","unstructured":"Kawasaki, K., Nogawa, H. & Nishijima, M. Identification of mouse MD-2 residues important for forming the cell surface TLR4-MD-2 complex recognized by anti-TLR4-MD-2 antibodies, and for conferring LPS and taxol responsiveness on mouse TLR4 by alanine-scanning mutagenesis. J. Immunol. 170, 413\u2013420 (2003).","journal-title":"J. Immunol."},{"key":"8582_CR63","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.4049\/jimmunol.1800380","volume":"201","author":"A Michaeli","year":"2018","unstructured":"Michaeli, A. et al. Computationally designed bispecific MD2\/CD14 binding peptides show TLR4 agonist activity. J. Immunol. 201, 3383\u20133391 (2018).","journal-title":"J. Immunol."},{"key":"8582_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/srep40791","volume":"7","author":"L Perrin-Cocon","year":"2017","unstructured":"Perrin-Cocon, L. et al. TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection. Sci. Rep. 7, 40791 (2017).","journal-title":"Sci. Rep."},{"key":"8582_CR65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1179\/096805104225003997","volume":"10","author":"H Fan","year":"2004","unstructured":"Fan, H. & Cook, J. A. Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res. 10, 71\u201384 (2004).","journal-title":"J. Endotoxin Res."},{"key":"8582_CR66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1034\/j.1600-065X.2000.917309.x","volume":"173","author":"R Medzhitov","year":"2000","unstructured":"Medzhitov, R. & Janeway, C. Jr. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89\u201397 (2000).","journal-title":"Immunol. Rev."},{"key":"8582_CR67","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/j.1462-5822.2005.00549.x","volume":"7","author":"SM Zughaier","year":"2005","unstructured":"Zughaier, S. M., Shafer, W. M. & Stephens, D. S. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell. Microbiol. 7, 1251\u20131262 (2005).","journal-title":"Cell. Microbiol."},{"key":"8582_CR68","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.4049\/jimmunol.181.3.1849","volume":"181","author":"H Shen","year":"2008","unstructured":"Shen, H., Tesar, B. M., Walker, W. E. & Goldstein, D. R. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J. Immunol. 181, 1849\u20131858 (2008).","journal-title":"J. Immunol."},{"key":"8582_CR69","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3389\/fimmu.2020.01210","volume":"11","author":"A Romerio","year":"2020","unstructured":"Romerio, A. & Peri, F. Increasing the chemical variety of small-molecule-based TLR4 modulators: an overview. Front. Immunol. 11, 1210 (2020).","journal-title":"Front. Immunol."},{"key":"8582_CR70","doi-asserted-by":"publisher","first-page":"31982","DOI":"10.1074\/jbc.M109.046383","volume":"284","author":"C Cekic","year":"2009","unstructured":"Cekic, C. et al. Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A.  J. Biol. Chem. 284, 31982\u201331991 (2009).","journal-title":"J. Biol. Chem."},{"key":"8582_CR71","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3389\/fimmu.2020.01207","volume":"11","author":"F Sato-Kaneko","year":"2020","unstructured":"Sato-Kaneko, F. et al. A novel synthetic dual agonistic Liposomal TLR4\/7 adjuvant promotes broad immune responses in an influenza vaccine with minimal reactogenicity. Front. Immunol. 11, 1207 (2020).","journal-title":"Front. Immunol."},{"key":"8582_CR72","doi-asserted-by":"publisher","first-page":"12261","DOI":"10.1021\/acs.jmedchem.1c00896","volume":"64","author":"FA Facchini","year":"2021","unstructured":"Facchini, F. A. et al. Synthetic Glycolipids as molecular vaccine adjuvants: mechanism of action in human cells and in vivo activity. J. Med. Chem. 64, 12261\u201312272 (2021).","journal-title":"J. Med. Chem."},{"key":"8582_CR73","doi-asserted-by":"publisher","first-page":"701445","DOI":"10.3389\/fimmu.2021.701445","volume":"12","author":"T Saito","year":"2021","unstructured":"Saito, T. et al. Small molecule potentiator of adjuvant activity enhancing survival to influenza viral challenge. Front. Immunol. 12, 701445 (2021).","journal-title":"Front. Immunol."},{"key":"8582_CR74","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJM199701093360202","volume":"336","author":"JA Stoute","year":"1997","unstructured":"Stoute, J. A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.  New. Engl. J. Med. 336, 86\u201391 (1997).","journal-title":"New. Engl. J. Med."},{"key":"8582_CR75","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1097\/INF.0b013e3181daf921","volume":"29","author":"J Diez-Domingo","year":"2010","unstructured":"Diez-Domingo, J. et al. Immunogenicity and Safety of H5N1 A\/Vietnam\/1194\/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.  Pediatr. Infect. Dis. J. 29, e35\u2013e46 (2010).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"8582_CR76","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","volume":"24","author":"SL Giannini","year":"2006","unstructured":"Giannini, S. L. et al. Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24, 5937\u20135949 (2006).","journal-title":"Vaccine"},{"key":"8582_CR77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","volume":"39","author":"G Del Giudice","year":"2018","unstructured":"Del Giudice, G., Rappuoli, R. & Didierlaurent, A. M. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin. Immunol. 39, 14\u201321 (2018).","journal-title":"Semin. Immunol."},{"key":"8582_CR78","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","volume":"38","author":"N Petrovsky","year":"2015","unstructured":"Petrovsky, N. Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug. Saf. 38, 1059\u20131074 (2015).","journal-title":"Drug. Saf."},{"key":"8582_CR79","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1056\/NEJM197405302902201","volume":"290","author":"DA Lipschitz","year":"1974","unstructured":"Lipschitz, D. A., Cook, J. D. & Finch, C. A. A clinical evaluation of serum ferritin as an index of iron stores.  New. Engl. J. Med. 290, 1213\u20131216 (1974).","journal-title":"New. Engl. J. Med."},{"key":"8582_CR80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcdb.2020.12.005","volume":"115","author":"D Haschka","year":"2021","unstructured":"Haschka, D., Hoffmann, A. & Weiss, G. Iron in immune cell function and host defense. Semin. Cell. Dev. Biol. 115, 27\u201336 (2021).","journal-title":"Semin. Cell. Dev. Biol."},{"key":"8582_CR81","doi-asserted-by":"publisher","unstructured":"Davis, J. S., Ferreira, D., Paige, E., Gedye, C. & Boyle, M. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin. Microbiol. Rev. 33, https:\/\/doi.org\/10.1128\/CMR.00035-19 (2020).","DOI":"10.1128\/CMR.00035-19"},{"key":"8582_CR82","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.3748\/wjg.v19.i23.3534","volume":"19","author":"G Tarantino","year":"2013","unstructured":"Tarantino, G., Scalera, A. & Finelli, C. Liver-spleen axis: intersection between immunity, infections and metabolism. World J. Gastroenterol. 19, 3534\u20133542 (2013).","journal-title":"World J. Gastroenterol."},{"key":"8582_CR83","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0028-3908(97)00044-0","volume":"36","author":"FG Boess","year":"1997","unstructured":"Boess, F. G. et al. Analysis of the ligand binding site of the 5-HT3 receptor using site directed mutagenesis: importance of glutamate 106. Neuropharmacology 36, 637\u2013647 (1997).","journal-title":"Neuropharmacology"},{"key":"8582_CR84","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12013-017-0821-6","volume":"76","author":"S Aliebrahimi","year":"2018","unstructured":"Aliebrahimi, S., Montasser Kouhsari, S., Ostad, S. N., Arab, S. S. & Karami, L. Identification of phytochemicals targeting c-Met kinase domain using consensus docking and molecular dynamics simulation studies. Cell. Biochem. Biophys. 76, 135\u2013145 (2018).","journal-title":"Cell. Biochem. Biophys."},{"key":"8582_CR85","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli, S. et al. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat. Protoc. 11, 905\u2013919 (2016).","journal-title":"Nat. Protoc."},{"key":"8582_CR86","doi-asserted-by":"publisher","unstructured":"Honegr, J. et al. Rational design of a new class of toll-like Receptor 4 (TLR4) Tryptamine related agonists by means of the structure- and ligand-based virtual screening for vaccine adjuvant discovery. Molecules 23, https:\/\/doi.org\/10.3390\/molecules23010102 (2018).","DOI":"10.3390\/molecules23010102"},{"key":"8582_CR87","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution. Drug. Discov. Today Technol. 1, 337\u2013341 (2004).","journal-title":"Drug. Discov. Today Technol."},{"key":"8582_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1093","volume":"1","author":"CJ Wienken","year":"2010","unstructured":"Wienken, C. J., Baaske, P., Rothbauer, U., Braun, D. & Duhr, S. Protein-binding assays in biological liquids using microscale thermophoresis. Nat. Commun. 1, 100 (2010).","journal-title":"Nat. Commun."},{"key":"8582_CR89","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1016\/j.vaccine.2011.01.110","volume":"29","author":"SM Faisal","year":"2011","unstructured":"Faisal, S. M. et al. Immunostimulatory and antigen delivery properties of liposomes made up of total polar lipids from non-pathogenic bacteria leads to efficient induction of both innate and adaptive immune responses. Vaccine 29, 2381\u20132391 (2011).","journal-title":"Vaccine"},{"key":"8582_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0022-1759(94)90034-5","volume":"174","author":"AA van de Loosdrecht","year":"1994","unstructured":"van de Loosdrecht, A. A., Beelen, R. H., Ossenkoppele, G. J., Broekhoven, M. G. & Langenhuijsen, M. M. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J. Immunol. Methods 174, 311\u2013320 (1994).","journal-title":"J. Immunol. Methods"},{"key":"8582_CR91","doi-asserted-by":"publisher","first-page":"985802","DOI":"10.3389\/fimmu.2022.985802","volume":"13","author":"VP Varma","year":"2022","unstructured":"Varma, V. P., Kadivella, M., Kumar, A., Kavela, S. & Faisal, S. M. LigA formulated in AS04 or Montanide ISA720VG induced superior immune response compared to alum, which correlated to protective efficacy in a Hamster model of leptospirosis. Front. Immunol. 13, 985802 (2022).","journal-title":"Front. Immunol."},{"key":"8582_CR92","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.taap.2009.07.009","volume":"240","author":"CR Patra","year":"2009","unstructured":"Patra, C. R. et al. In vivo toxicity studies of europium hydroxide nanorods in mice. Toxicol. Appl. Pharmacol. 240, 88\u201398 (2009).","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08582-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08582-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08582-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:04:05Z","timestamp":1759172645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08582-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8582"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-08582-y","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests. A patent has been granted for NSF-951 and its formulation AF007, titled \u201cSynthetic NSF-951 Agonist Compound and Preparation Thereof, Antigen-Alum-Synthetic NSF-951 Immuno-Formulation\u201d (Patent No. 569943, dated 21 August 2025).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1382"}}